Facial Emotion Recognition in Patients With Euthymic Bipolar Disorder I and II
NCT ID: NCT05922956
Last Updated: 2025-11-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
10 participants
INTERVENTIONAL
2020-04-01
2023-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study aims to evaluate facial emotion recognition in patients with bipolar I and II disorders compared to healthy controls, using the facial emotion recognition test (TREF). The objective of the present study is to compare TREF scores in a group of patients with bipolar 1, a group of patients with bipolar 2 disorder and a group with healthy controls. In addition, the investigators will investigate the relationships between TREF scores and levels of self-esteem and mental well-being.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neurofeedback for Bipolar Disorder
NCT05802446
Social Cognition, Memory, and Executive Functions in Bipolar Disorder and Major Depressive Disorder
NCT06740331
Emotion Recognition Modification for Bipolar Disorder
NCT02613104
Illness Representations in Patients With Bipolar Disorders
NCT03595670
Functional Remediation for Bipolar Disorder
NCT03403179
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
patients with bipolar disorder 1
Facial emotion recognition test
Facial emotion recognition test (TREF), questionnaires including self-administered questionnaires
patients with bipolar disorder 2
Facial emotion recognition test
Facial emotion recognition test (TREF), questionnaires including self-administered questionnaires
healthy controls
Facial emotion recognition test
Facial emotion recognition test (TREF), questionnaires including self-administered questionnaires
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Facial emotion recognition test
Facial emotion recognition test (TREF), questionnaires including self-administered questionnaires
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female patients, between 18 and 60 years old
* Diagnosis of Bipolar Disorder I or Bipolar Disorder II according to DSM-IV criteria, using the French version of the Mini-International Neuropsychiatric Interview (MINI)
* Strictly euthymic defined by Hamilton Depression Rating Scale (17 items) ≤ 5 and Young Mania Rating Scale ≤ 5 for at least two months.
* Native French speakers
* Affiliated to the French social security system
* Giving their written informed consent
Control group :
* Male or female control subjects, aged between 18 and 60 years old, assessed using TREF
* Native French speakers
* Giving their written informed consent
Exclusion Criteria
* History of mental retardation assessed by the French version of the National Adult Reading Test
* Neurological illness or any clinical condition that could affect cognitive performance (history of head injury with loss of consciousness lasting more than 5 minutes multiple sclerosis, stroke etc.)
* Electroconvulsive therapy within the last 6 months
* Alcohol and Drug dependence (except tobacco and caffeine) according to DSM-IV criteria using the French version of the Mini-International Neuropsychiatric Interview (MINI).
* Learning disability or difficulty with fluent use of the French language
* Patient with mandatory care
* Long-Term use of non-psychotropic medication with psychotropic effects (opiates, Baclofen)
Control group :
* History of mental retardation estimated by the French version of the National Adult Reading Test
* Neurological illness or any clinical condition that could affect cognitive performance (history of head injury with loss of consciousness lasting more than 5 minutes multiple sclerosis, stroke etc.)
* Current Mood disorder/ Lifetime Psychotic Disorder according to DSM-IV criteria using the French version of the Mini-International Neuropsychiatric Interview (MINI)
* Neither history of psychotic or affective disorders in a first-degree family member
* Alcohol and Drug dependence (except tobacco and caffeine) according to DSM-IV criteria using the French version of the Mini-International Neuropsychiatric Interview (MINI)
* Learning disability or difficulty with fluent use of the French language
* Long-Term use of non-psychotropic drugs with psychotropic effects (opiates, Baclofen) and psychotropic drugs
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier le Vinatier
UNKNOWN
Pôle Ressource Évaluation et Réhabilitation Psycho-sociale, EPSM de l'Oise
UNKNOWN
Centre de santé mentale MGEN
UNKNOWN
Centre Hospitalier Philippe Pinel, Amiens
UNKNOWN
Centre Hospitalier Universitaire, Amiens
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Amiens
Amiens, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PI2020_843_0009
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.